
``This compound binds directly to p23, leading to inactivation of the Hsp90 machine - without production of anti-apoptotic proteins - thus killing cancer cells,`` Chadli said in a statement.
``The idea here is that this will open a door for new ways of targeting Hsp90 by targeting its helper proteins, which may be used in combination with established Hsp90 inhibitors that are ongoing clinical trials.